Levo Therapeutics Receives Fast Track Designation From FDA for Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome

Announces Completion of Series B FinancingCHICAGO, Nov. 18, 2019 -- (Healthcare Sales & Marketing Network)-- Levo Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LV-101 (intra...Biopharmaceuticals, Neurology, Drug Delivery, FDA
Levo Therapeutics, Intranasal, Carbetocin, Prader-Willi Syndrome